Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Silo Pharma, Inc.SILO · Entity 8320 | Director | May 23, 2025 | May 27, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Silo Pharma, Inc.
Report date May 23, 2025 · Filed May 27, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.43 · Expires 2035-05-23 | Direct | 53,425 |
Reported balance
After 2025-05-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-23 · Grant · Acquired 50,000 · Balance 53,425 F1: The options were issued pursuant to the Issuer's 2020 Omnibus Equity Incentive Plan and one hundred percent (100%) of the shares subject to the option shall vest on the one (1)-year anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were issued pursuant to the Issuer's 2020 Omnibus Equity Incentive Plan and one hundred percent (100%) of the shares subject to the option shall vest on the one (1)-year anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 23, 2025 Filed May 27, 2025 23:03 UTC | Silo Pharma, Inc. SILO · Entity 8320 | GrantOptions (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001213900-25-047914 · ownership.xml · derivative · entry 1 Munoz Kevin · CIK 0001847763 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,425 Underlying: Common Stock · 50,000 shares Expires 2035-05-23 F1 · kind: The options were issued pursuant to the Issuer's 2020 Omnibus Equity Incentive Plan and one hundred percent (100%) of the shares subject to the option shall vest on the one (1)-year anniversary of the date of grant. Read SEC document |
| December 29, 2021 Filed Jan 4, 2022 02:55 UTC | Silo Pharma, Inc. SILO · Entity 8320 | GrantNon-Qualified Stock Option · Derivative | 171,233 | $0.00 Strike: $0.15 | $0.00 |
DisclosureSEC source: 0001213900-22-000363 · ownership.xml · derivative · entry 1 Munoz Kevin · CIK 0001847763 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,233 Underlying: Common Stock · 171,233 shares Expires 2026-12-29 F2 · price: The options were issued under the issuer's 2020 Omnibus Equity Incentive Plan. F1 · derivative.underlying_shares: Vests over the course of one year from grant with 100% vesting a year from the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.